Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cardiol Therapeutics (CRDL) Receivables - Other (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Receivables - Other readings, the most recent being $199111.7 for Q4 2022.

  • On a quarterly basis, Receivables - Other fell 26.48% to $199111.7 in Q4 2022 year-over-year; TTM through Dec 2022 was $199111.7, a 26.48% decrease, with the full-year FY2022 number at $199111.7, down 26.48% from a year prior.
  • Receivables - Other hit $199111.7 in Q4 2022 for Cardiol Therapeutics, up from $33300.6 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $270835.4 in Q4 2021 to a low of -$290046.8 in Q2 2021.
  • Median Receivables - Other over the past 3 years was $33300.6 (2022), compared with a mean of $28643.8.
  • The widest YoY moves for Receivables - Other: up 142.07% in 2022, down 26.48% in 2022.
  • Cardiol Therapeutics' Receivables - Other stood at $164249.4 in 2020, then surged by 64.89% to $270835.4 in 2021, then decreased by 26.48% to $199111.7 in 2022.
  • The last three reported values for Receivables - Other were $199111.7 (Q4 2022), $33300.6 (Q3 2022), and $49527.2 (Q2 2022) per Business Quant data.